CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Meloxicam

美洛昔康 杂质对照品Meloxicam Impurities

EPUSP38 个杂质条目38 impurity entries

本页汇总 美洛昔康 的 38 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 38 impurity reference standards of Meloxicam with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 美洛昔康(Meloxicam)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesDevelopment and validation of ultra-performance liquid chromatography method for the determination of meloxicam and its impurities in active pharmaceutical ingredients
    Annales pharmaceutiques francaises · 2018 · Louati K et al.  ·  PMID 29544974  ·  DOI
  2. 杂质研究Impurity studiesComparison of the processes photo-Fenton and photocatalysis with TiO(2) supported on non-woven fabric using a LED radiation in the degradation of the pharmaceutical meloxicam
    Environmental science and pollution research international · 2026 · do Nascimento GE et al.  ·  PMID 41619091  ·  DOI
  3. 杂质研究Impurity studiesMeloxicam emulgel potently suppressed cartilage degradation in knee osteoarthritis: Optimization, formulation, industrial scalability and pharmacodynamic analysis
    Colloids and surfaces. B, Biointerfaces · 2023 · Jyothi VGS et al.  ·  PMID 37348266  ·  DOI
  4. 分析方法Analytical MethodsAnalytical quality by design (AQbD)-based RP-HPLC method development and validation for concurrent determination of meloxicam and chlorhexidine in a novel dental in-situ gel for odontalgia
    Drug development and industrial pharmacy · 2026 · Kumar S et al.  ·  PMID 42259300  ·  DOI
  5. 分析方法Analytical MethodsValidation of assay indicating method development of meloxicam in bulk and some of its tablet dosage forms by RP-HPLC
    SpringerPlus · 2014 · Sahoo NK et al.  ·  PMID 24711980  ·  DOI

美洛昔康 —— 原料药与杂质对照品Meloxicam — drug substance & impurities

共 39 个条目(含原料药本体)39 items incl. the drug substance
Meloxicam structure
EP原料药 APIAPI
美洛昔康Meloxicam
Meloxicam
CAS No.71125-38-7
Chemical FormulaC14H13N3O4S2
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 2 (Meloxicam EP Impurity B) structure
EPB
美洛昔康杂质2 (美洛昔康EP杂质B)Meloxicam Impurity 2 (Meloxicam EP Impurity B)
Meloxicam Impurity 2 (Meloxicam EP Impurity B)
CAS No.7305-71-7
Chemical FormulaC4H6N2S
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 3 (Meloxicam EP Impurity C) structure
EPC
美洛昔康杂质3 (美洛昔康EP杂质C)Meloxicam Impurity 3 (Meloxicam EP Impurity C)
Meloxicam Impurity 3 (Meloxicam EP Impurity C)
CAS No.1262333-25-4
Chemical FormulaC15H15N3O4S2
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 4 (Meloxicam EP Impurity D) structure
EPD
美洛昔康杂质4 (美洛昔康EP杂质D)Meloxicam Impurity 4 (Meloxicam EP Impurity D)
Meloxicam Impurity 4 (Meloxicam EP Impurity D)
CAS No.1331636-17-9
Chemical FormulaC16H17N3O4S2
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 4-d5 (Meloxicam EP Impurity D-d5) structure
EPD-D5
美洛昔康杂质4-d5 (美洛昔康EP杂质D-d5)Meloxicam Impurity 4-d5 (Meloxicam EP Impurity D-d5)
Meloxicam Impurity 4-d5 (Meloxicam EP Impurity D-d5)
CAS No.1331635-89-2
Chemical FormulaC16H12D5N3O4S2
Purity>95%询价On request
Meloxicam Impurity 7 (Meloxicam USP Related Compound D) structure
USPD
美洛昔康杂质7 (美洛昔康USP相关化合物D)Meloxicam Impurity 7 (Meloxicam USP Related Compound D)
Meloxicam Impurity 7 (Meloxicam USP Related Compound D)
CAS No.1391051-96-9
Chemical FormulaC15H15N3O4S2
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 7-d3 (Meloxicam USP Related Compound D-d3) structure
USPD-D3
美洛昔康杂质7-d3 (美洛昔康USP相关化合物D-d3)Meloxicam Impurity 7-d3 (Meloxicam USP Related Compound D-d3)
Meloxicam Impurity 7-d3 (Meloxicam USP Related Compound D-d3)
CAS No.1794737-37-3
Chemical FormulaC15H12D3N3O4S2
Purity>95%询价On request
Meloxicam Impurity 1 structure
1
美洛昔康杂质1Meloxicam Impurity 1
Meloxicam Impurity 1
CAS No.101855-37-2
Chemical FormulaC13H13NO4
Purity>95%现货In stock
10mg25mg50mg100mg
Meloxicam Impurity 8 structure
8
美洛昔康杂质8Meloxicam Impurity 8
Meloxicam Impurity 8
CAS No.632-25-7
Chemical FormulaC7H6O5S
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 9 structure
9
美洛昔康杂质9Meloxicam Impurity 9
Meloxicam Impurity 9
CAS No.125372-22-7
Chemical FormulaC8H9NO4S
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 10 structure
10
美洛昔康杂质10Meloxicam Impurity 10
Meloxicam Impurity 10
CAS No.130262-93-0
Chemical FormulaC14H11N3O6S2
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 11 structure
11
美洛昔康杂质11Meloxicam Impurity 11
Meloxicam Impurity 11
CAS No.130262-92-9
Chemical FormulaC14H14ClN3O5S2
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 12 structure
12
美洛昔康杂质12Meloxicam Impurity 12
Meloxicam Impurity 12
CAS No.881399-30-0
Chemical FormulaC16H17N3O4S2
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 13 structure
13
美洛昔康杂质13Meloxicam Impurity 13
Meloxicam Impurity 13
CAS No.892395-41-4
Chemical FormulaC15H15N3O4S2
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 14 structure
14
美洛昔康杂质14Meloxicam Impurity 14
Meloxicam Impurity 14
CAS No.24683-25-8
Chemical FormulaC10H10N2O4S
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 15 structure
15
美洛昔康杂质15Meloxicam Impurity 15
Meloxicam Impurity 15
CAS No.82514-69-0
Chemical FormulaC6H6N2O3S
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 16 structure
16
美洛昔康杂质16Meloxicam Impurity 16
Meloxicam Impurity 16
CAS No.1076199-65-9
Chemical FormulaC20H27N3O5S2Si
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 17 structure
17
美洛昔康杂质17Meloxicam Impurity 17
Meloxicam Impurity 17
CAS No.1797124-56-1
Chemical FormulaC14H13N3O5S2
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 18 structure
18
美洛昔康杂质18Meloxicam Impurity 18
Meloxicam Impurity 18
CAS No.1797982-60-5
Chemical FormulaC20H27N3O5S2Si
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 19 structure
19
美洛昔康杂质19Meloxicam Impurity 19
Meloxicam Impurity 19
CAS No.1220040-23-2
Chemical FormulaC6H8N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 20 structure
20
美洛昔康杂质20Meloxicam Impurity 20
Meloxicam Impurity 20
CAS No.99219-51-9
Chemical FormulaC10H7NNa2O5S
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 21 structure
21
美洛昔康杂质21Meloxicam Impurity 21
Meloxicam Impurity 21
CAS No.113913-36-3
Chemical FormulaC12H15NO5S
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 22 structure
22
美洛昔康杂质22Meloxicam Impurity 22
Meloxicam Impurity 22
CAS No.13165-80-5
Chemical FormulaC7H6O4S
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 23 structure
23
美洛昔康杂质23Meloxicam Impurity 23
Meloxicam Impurity 23
CAS No.1145656-36-5
Chemical FormulaC15H15N3O4S2
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 28 structure
28
美洛昔康杂质28Meloxicam Impurity 28
Meloxicam Impurity 28
CAS No.41731-33-3
Chemical FormulaC3H3BrN2S
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 29 Monomer structure
29
美洛昔康杂质29 单体Meloxicam Impurity 29 Monomer
Meloxicam Impurity 29 Monomer
CAS No.33124-04-8
Chemical FormulaC4H6N2O
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 29 structure
29
美洛昔康杂质29Meloxicam Impurity 29
Meloxicam Impurity 29
CAS No.929568-25-2
Chemical FormulaC4H6N2O·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 30 structure
30
美洛昔康杂质30Meloxicam Impurity 30
Meloxicam Impurity 30
CAS No.899020-26-9
Chemical FormulaC9H9NO3S
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 32 structure
32
美洛昔康杂质32Meloxicam Impurity 32
Meloxicam Impurity 32
CAS No.1865298-74-3
Chemical FormulaC6H8N2O2S
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 33 Sodium structure
33
美洛昔康杂质33 钠盐Meloxicam Impurity 33 Sodium
Meloxicam Impurity 33 Sodium
CAS No.1008-72-6
Chemical FormulaC7H5O4S-·Na+
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 33 structure
33
美洛昔康杂质33Meloxicam Impurity 33
Meloxicam Impurity 33
CAS No.91-25-8
Chemical FormulaC7H6O4S
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 34 structure
34
美洛昔康杂质34Meloxicam Impurity 34
Meloxicam Impurity 34
CAS No.5363-54-2
Chemical FormulaC7H6O4S
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 36 structure
36
美洛昔康杂质36Meloxicam Impurity 36
Meloxicam Impurity 36
CAS No.99171-11-6
Chemical FormulaC4H6N2S2
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 37 structure
37
美洛昔康杂质37Meloxicam Impurity 37
Meloxicam Impurity 37
CAS No.96-50-4
Chemical FormulaC3H4N2S
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 38 structure
38
美洛昔康杂质38Meloxicam Impurity 38
Meloxicam Impurity 38
CAS No.73732-22-6
Chemical FormulaC8H8O5S
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 40 structure
40
美洛昔康杂质40Meloxicam Impurity 40
Meloxicam Impurity 40
CAS No.120740-06-9
Chemical FormulaC5H7ClN2S
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 41 structure
41
美洛昔康杂质41Meloxicam Impurity 41
Meloxicam Impurity 41
CAS No.82514-60-1
Chemical FormulaC8H10N2O3S
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 42 structure
42
美洛昔康杂质42Meloxicam Impurity 42
Meloxicam Impurity 42
CAS No.57897-77-5
Chemical FormulaC8H8O5S
Purity>95%询价On request
10mg25mg50mg100mg
Meloxicam Impurity 43 structure
43
美洛昔康杂质43Meloxicam Impurity 43
Meloxicam Impurity 43
CAS No.1566160-20-0
Chemical FormulaC7H8N2O3S
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

美洛昔康 —— 研究文献与合成路线Meloxicam — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 美洛昔康 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Meloxicam. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Stability Indicating HPTLC Determination of Meloxicam
    Desai N, Amin P · Indian journal of pharmaceutical sciences · 2008 · 被引 2cited 2
  2. Construction of artificial peroxidase based on myoglobin scaffold for efficient degradation of meloxicam
    Zhang W, Yang Y, Meng X, et al. · Journal of inorganic biochemistry · 2025 · 被引 1cited 1
  3. Development and validation of ultra-performance liquid chromatography method for the determination of meloxicam and its impurities in active pharmaceutical ingredients
    Louati K, Bargaoui I, Safta F · Annales pharmaceutiques francaises · 2018 · 被引 2cited 2
  4. Development and validation of NIR-chemometric methods for chemical and pharmaceutical characterization of meloxicam tablets
    Tomuta I, Iovanov R, Bodoki E, et al. · Drug development and industrial pharmacy · 2014 · 被引 17cited 17
  5. Eco-friendly four spectrophotometric approaches for the simultaneous determination of the recently FDA-approved combination, bupivacaine and meloxicam in pharmaceutical dosage forms
    Radwan AS, Salim MM, Belal F, et al. · Scientific reports · 2024 · 被引 2cited 2
  6. Determination of meloxicam in bulk and pharmaceutical formulations
    Zawilla NH, Abdul-Azim Mohammad M, El kousy NM, et al. · Journal of pharmaceutical and biomedical analysis · 2003 · 被引 8cited 8

合成与制备工艺专利Synthesis & process patents

  1. PROCESS FOR PREPARATION OF HIGH-PURITY MELOXICAM AND MELOXICAM POTASSIUM SALT
    MEZEI TIBOR, SIMIG GYULA, MOLNAR ENIKO, LUKACS GYULA, et al. · 公开号 US2012035162US2012035162 · 2012
  2. PROCESS FOR THE PURIFICATION OF MELOXICAM
    CROMIE LILIAN, MCELROY LIAM, GARRET MARK · 公开号 MX2009005328MX2009005328 · 2009
  3. Process for preparation of high-purity meloxicam and meloxicam potassium salt
    MEZEI TIBOR, SIMIG GYULA, MOLNAR ENIKO, LUKACS GYULA, et al. · 公开号 SK50932007SK50932007 · 2008
  4. PROCESS FOR PREPARATION OF HIGH-PURITY MELOXICAM AND MELOXICAM POTASSIUM SALT
    MEZEI TIBOR, SIMIG GYULA, MOLNAR ENIKO, LUKACS GYULA, et al. · 公开号 SI1828178TSI1828178T · 2011
  5. Process for Preparation of High-Purity Meloxicam and Meloxicam Potassium Salt
    MEZEI TIBOR, SIMIG GYULA, MOLNAR ENIKO, LUKACS GYULA, et al. · 公开号 US2009215757US2009215757 · 2009

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

美洛昔康 杂质谱研究要点Meloxicam — impurity profiling notes

下面这些是拿到 美洛昔康 的 39 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 39 impurity entries for Meloxicam, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances